Seegene Inc (096530) - Total Assets
Based on the latest financial reports, Seegene Inc (096530) holds total assets worth ₩1.27 Trillion KRW (≈ $858.01 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Seegene Inc - Total Assets Trend (2012–2025)
This chart illustrates how Seegene Inc's total assets have evolved over time, based on quarterly financial data. Also see Seegene Inc stock valuation for the company's overall valuation and market capitalisation.
Seegene Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Seegene Inc's total assets of ₩1.27 Trillion consist of 64.6% current assets and 35.4% non-current assets. Review Seegene Inc debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 18.3% |
| Accounts Receivable | ₩97.59 Billion | 7.9% |
| Inventory | ₩82.20 Billion | 6.7% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩19.60 Billion | 1.6% |
| Goodwill | ₩9.00 Billion | 0.7% |
Asset Composition Trend (2012–2025)
This chart illustrates how Seegene Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 096530 share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Seegene Inc's current assets represent 64.6% of total assets in 2025, an increase from 62.9% in 2012.
- Cash Position: Cash and equivalents constituted 18.3% of total assets in 2025, up from 5.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 7.9% of total assets.
Seegene Inc Competitors by Total Assets
Key competitors of Seegene Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Seegene Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.62 | 4.71 | 3.47 |
| Quick Ratio | 4.19 | 4.12 | 2.51 |
| Cash Ratio | 0.00 | 0.00 | 1.48 |
| Working Capital | ₩642.03 Billion | ₩601.20 Billion | ₩643.03 Billion |
Seegene Inc - Advanced Valuation Insights
This section examines the relationship between Seegene Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.33 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 2.5% |
| Total Assets | ₩1.24 Trillion |
| Market Capitalization | $1.00 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Seegene Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Seegene Inc's assets grew by 2.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Seegene Inc (2012–2025)
The table below shows the annual total assets of Seegene Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩1.24 Trillion ≈ $837.48 Million |
+2.53% |
| 2024-12-31 | ₩1.21 Trillion ≈ $816.80 Million |
-3.69% |
| 2023-12-31 | ₩1.25 Trillion ≈ $848.09 Million |
-10.02% |
| 2022-12-31 | ₩1.39 Trillion ≈ $942.51 Million |
-6.64% |
| 2021-12-31 | ₩1.49 Trillion ≈ $1.01 Billion |
+36.10% |
| 2020-12-31 | ₩1.09 Trillion ≈ $741.78 Million |
+459.27% |
| 2019-12-31 | ₩195.72 Billion ≈ $132.63 Million |
+19.48% |
| 2018-12-31 | ₩163.81 Billion ≈ $111.01 Million |
-0.63% |
| 2017-12-31 | ₩164.84 Billion ≈ $111.71 Million |
-20.60% |
| 2016-12-31 | ₩207.62 Billion ≈ $140.70 Million |
+6.99% |
| 2015-12-31 | ₩194.05 Billion ≈ $131.50 Million |
+40.15% |
| 2014-12-31 | ₩138.45 Billion ≈ $93.83 Million |
+7.30% |
| 2013-12-31 | ₩129.04 Billion ≈ $87.45 Million |
+54.32% |
| 2012-12-31 | ₩83.62 Billion ≈ $56.67 Million |
-- |
About Seegene Inc
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection … Read more